On 30 March 2026, the FDA sent compliance reminders to more than 2,200 sponsors and researchers linked to over 3,000 registered clinical trials. If your trial is on that list, here is what the requirement means in practice and what submitting results actually involves. 

What the FDA is asking for

Under the FDA Amendments Act of 2007 (FDAAA 801), most clinical trials with a US nexus and an FDA-regulated product must submit summary results to ClinicalTrials.gov within one year of the primary completion date. This applies whether results are positive, negative or inconclusive. 

The FDA’s own analysis found that 29.6% of studies highly likely to fall under mandatory reporting have no results submitted. The March reminders are an opportunity to comply before the agency considers further action. 

Non-compliance can lead to Pre-Notices or Notices of Noncompliance and ultimately to fines exceeding $10,000 per day for continued failure to report. 

How much work is actually involved

This is the question most sponsors ask first. The answer is more straightforward than many expect. 

A single‑study results submission to ClinicalTrials.gov typically runs over a structured 3‑week end‑to‑end process. That is a defined scope not an open-ended commitment.

Why the FDA is acting now

The FDA has been direct about its rationale. Negative data is routinely withheld, creating a publication bias that distorts the public record of drug development. Clinicians and researchers are making decisions based on an incomplete picture. 

In the words of FDA Commissioner Marty Makary, M.D., M.P.H.: “Far too often, companies are suppressing unfavorable clinical trial results and keeping them secret from patients and the scientific community. Those sponsoring clinical trials have an ethical obligation to make results public regardless of the data’s influence on the company’s share price.” 

This is not a US-only trend. The European Medicines Agency (EMA) removed its deferral mechanism in October 2023, closing a route that had previously allowed sponsors to delay publication of certain data and documents for up to seven years after trial completion. 

How TFS can help

Results submission to ClinicalTrials.gov is not new to our Medical Writing team. We have supported sponsors through this process and understand what the work involves from end to end. 

Our experience includes guiding sponsors through results posting across multiple therapeutic areas and development phases. Our team works directly from the final clinical study report or in parallel with tables, figures and listings when timelines are tight. We extract, validate and finalize all required sections: participant flow, baseline characteristics, outcome measures, adverse events and study limitations. Sponsors receive a complete PDF for review before anything is submitted, and we incorporate feedback before the submission goes in. 

If you have received a reminder from the FDA or if you have completed or terminated trials approaching their reporting deadline, we can help you scope the work and get it done.